P-CNS newsletter: Spring 2021

As we all emerge from a long period of isolation into the spring sunshine, we send our best wishes to our supporters and followers for their continued good health. We hope that you’ve all managed to navigate your way through this difficult period without too much distress and disruption and this weekend you can enjoy some of the joys of spring, whether in the garden or our for a walk.

Here’s the latest news from the P-CNS:

RCGP One Day Essentials: Recordings now online

We were pleased to co-host a neurology-focused One Day Essentials event with the RCGP in January. Over 100 people attended virtually on the day. Recordings from the event are now available to watch on the RCGP’s website and are free to all those who registered for the January event. If you didn’t attend in January but still want to watch the recordings, the standard ticket price applies. 

You can find the recordings here.

Curiate, a new e-learning platform by Innervate

Curiate is a new online learning platform from Innervate Ltd in partnership with the Skills Network. It has been launched with a range of ready-made online short courses support Continuing Professional Development (CPD). We have plans to create new bespoke neurology related courses in partnership, as the platform grows.

All of the currently courses are short bite-sized interactive and engaging CPD models. They are designed to take an average of two hours to complete. They are auto-marked, meaning that feedback is instant, and a CPD certificate is issued on completion of all courses. You can browse or sign up to any of the Curiate course from this address. If you are interest to work with us to build new course material then please email in at info@p-cns.org.uk.

Bolt Burdon Kemp: Our newest sponsor

We are delighted to announce Bolt Burdon Kemp as our newest corporate sponsor!

Bolt Burdon Kemp is a leading firm of solicitors for serious injury claims.

Their specialist brain injury solicitors have over 30 years’ experience in achieving strong results in complex claims involving adults and children with brain injuries. They are recognised as a leading firm in the field of head and brain injury by the independent Chambers and Partners and Legal 500 guides.

Bolt Burdon Kemp’s brain injury specialists understand the far reaching effects of neurological injury on an individual and know the importance of prompt diagnosis, treatment and rehabilitation. They place clients’ wellbeing at the centre of their actions and seek to support them outside of legal process.

Bolt Burdon Kemp’s partnership will help to support the Primary Care and Community Neurology Society’s work to enhance the delivery and quality of care to those with neurological conditions.

How are you Feeling?

We wanted to alert you to a survey that is being run by Innervate Ltd and invite you and any of your colleagues or friends and relatives to take part. The survey is part of wider research to explore whether better recognition of emotions arising from either a physical or mental life event can help to support the health and wellbeing of people. Read more about the survey and see some interim observations here.

MND Community of Practice

Our partners at the MND Association have launched the MND Professionals’ Community of Practice (CoP). The Community is for health and social care professionals practising or interested in the field of MND care. It’s a peer-led group of health and social care professionals encouraging and supporting the development of good care for people living with, or affected by, MND.

Being an active member of the CoP could count towards your professional CPD requirement. To find out more or join the Community of Practice click here.


NeuroLifeNow is a new app and website for people with neurological conditions to share their experiences. The app has been developed by the Brain and Spine Foundation and the Neurological Alliance.

The platform allows for the routine collection of patient experience data, so we can get a real time view of if and how people with neurological conditions are accessing services. This is the pilot phase of the platform, which will run until the end of March 2021. Gathering up this sort of data, in the current circumstances, is of course extremely timely.

Please do download and share the app:

  • You can download it from the Apple store here.
  • The Google Play store here.
  • Or use the web platform here.

Thank you in advance for your support.

Brain Tumour Charity

The Brain Tumour Charity has put together an interactive step-by-step guide for people who have been diagnosed with a brain tumour. The guide covers every part of the patient experience from first symptoms to diagnosis and treatment. It’s a great resource which has been built in collaboration with doctors and people with brain tumour experience, so be sure to share it with anyone who could benefit!

In other news:

NIHR alert: Palliative care for neurological conditions 

A new NIHR trial of short-term integrative palliative care (SIPC) in neurological conditions has revealed that SIPC gives the same benefits to patients as standard care at a lower cost per patient. The OPTCARE study, the largest study of palliative care in a variety of neurological conditions, compared two groups of patients receiving SIPC and standard end-of-life treatment for neurological conditions. The findings of the trial can be accessed here.

New neuro rehabilitation centre opened in Salisbury
South Newton Hospital, an independent specialist neurorehabilitation centre in Salisbury, opened its doors for the first time last month. Renovo Care and their parent investment firm Blantyre Capital have invested £1m in the site, which can currently accommodate 17 patients and includes en-suite single bedrooms, a pool, a gym and a mature garden. South Newton Hospital is the fourth neurorehabilitation site that Renovo have acquired since the company’s incorporation in January 2020. Read more here.

From the NHS Networks

The stress-resistant manager: building your resilience

Act FAST campaign to improve stroke outcomes

Ebrain—a leading provider of independent online learning in neurosciences

When did you last look at ebrain? Did you know that all members of this society have free access to ebrain (www.ebrain.net)? It is a non-commercial, charitable initiative that we should all be supporting as much as possible.

Ebrain has over 500 e-learning sessions approved to provide CPD by the Royal College of Physicians, and as the COVID 19 virus has resulted in a lot of CPD events being cancelled it may be a good option for many of us.

There are also practice MCQs, virtual patients, some webinars and a whole load of other content.  If anyone in the society has ideas on how it can be developed further to help support us then please contact admin@ebrain.net

To find out more about how you can access Ebrain for free visit our website here.  

To reach any of our previous newsletters click here.

Corporate Partner News

In this section our corporate partners can relay their latest news. Over the coming weeks we start to populate this page with news links.

For instance to read about the latest news from the Parkinson’s Excellence Network, click on the link below.

Click here!

Neurodigest News

Neurodigest is our journal produced in partnership with Advances in Clinical Neuroscience and Rehabilitation, designed to help keep you up to date with developments in neurology to support the management of people with neurological conditions in primary care and the wider community setting. Our latest newsletter can be read from here.

Advances in Clinical Neuroscience and Rehabilitation – Latest News

Advances in Clinical Neuroscience and Rehabilitation (ACNR) is a peer reviewed open access neurology journal, based in the UK and with international readership. ACNR aims to keep busy practicing neurologists and rehabilitation specialists up-to-date with the latest advances in their fields,  including areas of neurology and neuroscience outside their main area of sub-specialty interest. The latest ACNR newsletter can be read from here.


IBTA e-News

The monthly bulletin for our
international brain tumour community
March 2021

Leading news

‘Special Collection’ on brain tumour diagnosis and management now available in the Cochrane Library

The Cochrane Library – a free-to-access collection of high-quality, independent evidence to inform healthcare decision-making – has published a new Cochrane ‘Special Collection’ dedicated to brain tumour diagnosis and management. It addresses issues such as achieving prompt, safe and accurate diagnoses; shared decision making and risk sharing in glioma as well as understanding the best treatment when decisions are difficult. This publication reflects a collaboration between CochraneThe James Lind Alliancebrainstrust the National Institute for Health Research, the National Cancer Research Institute and brain tumour patients themselves, and brings together years of collaborative effort into a resource that is relevant for people living with a brain tumour. Read more.

New EURACAN website launches

A new website has launched for EURACAN, the European Reference Network (ERN) for Rare Adult Solid Tumours. ERNS are virtual patient-centred networks involving healthcare providers and patient representatives across Europe. Working together, these stakeholders aim to tackle complex or rare diseases and conditions, such as brain tumours, that require highly specialised care and concentrated knowledge and resources.  For EURACAN information on brain and CNS tumours, read more here

First official meeting of SISAQOL-IMI held this month

The first official meeting of SISAQOL-IMI – a public/private, multidisciplinary partnership involving 42 stakeholder groups representing academia, industry, patient organisations, regulators and cancer institutes – took place virtually on 17th and 18th March. The four-year project will work towards generating recommendations to standardise the use, analysis and interpretation of patient reported outcome (PRO) data, such as health-related quality of life and symptoms, in cancer clinical trials. The IBTA is one of the project’s member organisations together with other patient advocacy groups who, like the IBTA, are part of WECAN (Workgroup of European Cancer Patient Advocacy Networks). The IBTA Chair, Kathy Oliver said: “SISAQOL’s work highlights the vital importance of including PROs in all cancer research studies – including those for brain tumours – and will also help ensure that the issues which really matter to patients, and significantly impact them, are part of treatment decision-making in a much more consistent and accurate manner.” Read more.

Glioblastoma survival is linked to financial income in Italy, study finds

Socioeconomic status appears to be tightly correlated to survival in glioblastoma, according to a study published in the European Journal of Cancer. Even though Italy offers a universal, largely free and relatively comprehensive healthcare service to its population, this study highlights that income remains a factor affecting clinical outcomes. Read more (payment/subscription needed for full article).

All.Can infographic on why efficient cancer care matters is published

 All.Can – an initiative established in 2016 in which the IBTA is a founding member –  is a global, multi-stakeholder initiative to inform and generate political and public engagement on the need to improve efficiency in cancer care, by focusing on what really matters to patients and society. All.Can seeks to make sure resources are directed towards achieving better health outcomes while contributing to health systems’ overall sustainability.  All.Can has just released a new infographic, explaining why cancer care efficiency matters and how it can be improved across the entire cancer care journey and at different system levels by drawing on examples of good practice around the world.  View the infographic here

Treatment news 

Results published of phase 2 trial of cognitive effects of proton radiotherapy versus intensity modulated radiotherapy in newly diagnosed glioblastoma

Results from a phase 2 trial published in the journal Neuro-Oncology comparing the mental status changes (cognitive side effects) after treatment with either proton radiation (PT) or intensity-modulated radiotherapy (IMRT) has reported results which found that there was no difference in delayed time to cognitive failure (a drop in a mental ability not due to chance), progression-free survival, or overall survival between the two treatment approaches. However, patients receiving proton radiation therapy experienced fewer toxicities (grade 2 or higher) and reported less fatigue than patients receiving intensity-modulated radiotherapy. The researchers state that: “Larger randomized trials are needed to determine the potential of PT such as dose escalation for glioblastoma and cognitive preservation in patients with lower grade gliomas with a longer survival time.” Read more.

New ‘shear wave’ ultrasound scan may help surgeons more accurately detect residual brain tumour during surgery

A new ultrasound scanning technology called shear wave elastography may aid surgeons to remove residual brain tumour tissue at the time of surgery, according to a multi-centre study published in the journal Frontiers in Oncology. Shear wave elastography uses the sideways ripples of ultrasound energy throughout the brain to measure tissue stiffness and so distinguish brain cancer tissue from healthy brain. Researchers performed shear wave scans and conventional 2D ultrasounds before, during and after tumour removal, alongside asking the surgeons to identify cancerous tissue. The researchers report that, with an accuracy equivalent to ‘gold standard’ post-operative MRI scans, shear wave elastography was better at detecting residual tumour tissue after initial resection than either a standard ultrasound or a surgeon’s evaluation (94% sensitivity, compared with 73% and 36% respectively), potentially offering a cost- and time-effective way to maximise tumour resection. Read more.

Nine brain tumour centres in UK are awarded Tessa Jowell Centre of Excellence status

Nine National Health Service (NHS) hospital brain tumour centres in the UK have been recognised as a ‘Tessa Jowell Centre of Excellence’ following the first round of expert-led assessments by the Tessa Jowell Brain Cancer Mission. The Tessa Jowell Centre of Excellence designation recognises and awards neuro-oncology centres for their excellence in patient care. Assessments were made through rigorous virtual site visits and led by a committee of experts in the field and backed up by patient feedback. Read more.

Research news 

Experimental IDH1 vaccine for high-grade glioma is safe, researchers report, and triggers anti-tumour immune response in phase 1 trial results.

A paper published in the journal Nature has reported promising results from a phase 1 human trial involving 33 patients testing a novel vaccine in diffuse gliomas designed to target cells carrying a mutated IDH1 gene. Over 70% of low-grade gliomas have a single gene mutation affecting an enzyme called isocitrate dehydrogenase 1 (IDH1), a status which carries an improved prognosis. The study’s researchers report that data from the trial suggests the vaccine is safe and stimulates a significant immune response that slows tumour progression.  A larger phase 2 trial is currently being planned. Read more.

Most glioblastoma patients are not eligible to enrol on clinical trials, study finds

A majority of glioblastoma patients are being systematically excluded from clinical trials because of stringent eligibility criteria and potentially skewing results, according to a study published in Neuro-Oncology Advances. By analysing the outcomes and details of newly diagnosed glioblastoma  patients in two Norwegian cancer patient databases from 2012 to 2017, the research team found that 57% of patients did not meet standard eligibility criteria commonly used in phase 3 clinical trials. They found the majority of patients who enrol in such trials are typically younger, healthier and with fewer other medical conditions. The paper’s authors argue that this bias should be taken into consideration when trial results are used to guide treatment as trial results may not reflect what happens in the real world. Read more.

Clinical trial finds cannabinoid mouth spray taken with temozolomide chemotherapy is safe and well tolerated in recurrent glioblastoma

Published in the British Journal of Cancer, a phase 1b clinical trial of a cannabinoid mouth spray (nabiximols) combined with temozolomide chemotherapy in recurrent glioblastoma patients has found it to be safe, well tolerated, and that it did not interact with other drugs. The nabiximols spray contains two active substances found in cannabis, THC and CBD, and doses were personalised for each patient. The randomised, placebo-controlled trial was designed to test how the drug is handled in the body, although a later analysis of survival in this small trial found that survival at 1 year was 83% for nabiximols and 44% for placebo-treated patients. The researchers conclude that “the observed differences support further exploration in an adequately powered randomised controlled trial”. Read more. An accompanying editorial is available to read here.

Researchers reveal how single genetic mutation affects the location of childhood high grade gliomas

By growing immature brain cells in the lab to simulate the developing brain, researchers were able to explore the genetic drivers of which region in the brain a paediatric high-grade glioma will develop, according to a study published in Cell Stem Cell. It has been shown in previous research that whether a paediatric high-grade glioma grows in the ‘forebrain’ (the upper parts of the brain) or the ‘hindbrain’ (the lower regions and brainstem) appears to depend on whether the genetic code for one protein, histone H3 (a type of spool-like protein around which DNA coils), is mutated in one of two ways. In these new findings, researchers grew developing brain cells in the lab to simulate the different brain regions. They found that forebrain tumours (which are associated with an H3.3-G34R mutation) disrupt a specific gene-controlling molecule (ZMYND11) in the forebrain cells, effectively locking them into a perpetual immature state. Read more.

Research finds that cerebrospinal fluid sample may be able to predict effectiveness of immunotherapy in brain metastases patients

According to a study published in Nature Communications, it may be possible to predict whether a person with brain metastases will respond to a variety of different ‘checkpoint’ immunotherapies, such as anti-PD1, anti-PD-L1, and anti-CTLA4 drugs, through a test of their cerebrospinal fluid (the liquid which bathes the brain and spinal cord). Researchers compared the types of immune cells in the brain tumours of 48 brain metastasis patients with the immune cells found in their cerebrospinal fluid. From these findings they were able to identify those individuals whose tumours contained classes of T-cell type immune cells that would be activated by immunotherapies. Read more.

New stem cell therapy for breast cancer brain metastases developed in animal study

A targeted stem-cell treatment for breast cancer brain metastases has been developed in mice, according to a paper published in Science Advances. After developing mouse ‘models’ of basal-like breast cancer (a particularly aggressive form of breast cancer) that mimic the human disease, the researchers identified two molecular targets on the brain tumour cells (EGFR and DR4/5). They then engineered a protein that would both block EGFR and stimulate DR4/5, and then used modified stem cells (immature, undeveloped cells), which could pass through the blood-brain barrier to deliver the protein to the target. In those animals treated with this stem cell therapy, brain tumour growth was slowed and survival was significantly extended. Read more.

Meningioma progression score for predicting risk of recurrence developed; four subtypes identified

A new scoring system for predicting how an individual’s meningioma will develop and respond to treatment has been published in the journal Cancer. Through genetic analysis of 179 meningiomas correlated with patient outcome, four meningioma subtypes were identified. A rating system called MPscore based on the various factors linked to prognosis was devised and then tested on three separate cohorts of patients to validate its effectiveness. The paper’s authors hope the score will help clinicians identify meningioma patients most at risk of experiencing recurrence after surgery. Read more.

Phase 0 trial of pamiparib in newly diagnosed and recurrent glioblastoma begins

The Ivy Brain Tumor Center at Barrow Neurological Institute, Phoenix, Arizona, USA has announced the first patient has been treated in a Phase 0 clinical trial of pamiparib in newly diagnosed and recurrent glioblastoma. The trial seeks to confirm that pamiparib is capable of crossing the blood-brain barrier, after which patients with positive results may continue to receive treatment in the phase 2 section of the trial. Pamiparib blocks PARP enzymes, which cancer cells use to repair their damaged DNA. Read more (official press release). Trial information available here (Clinicaltrials.gov). 

Childhood brain tumour survivors much more likely to be overweight or obese, study finds

Published in the Journal of Clinical Oncology, a study of 661 children who survived a brain tumour has found that one third become overweight, obese, or had gained a significant amount of weight during the follow-up period (7.3 years on average). Unlike other similar research, this Dutch study excluded patients with craniopharyngiomas or pituitary tumours – which are known to directly affect hormone levels. However, the individuals who were overweight or obese were found to be more likely to subsequently develop problems with how the hypothalamus and pituitary regions regulate hormone levels. The study’s authors propose that increased weight in a childhood brain tumour survivor may be an early indicator of hypothalamic-pituitary dysfunction. Read more (free registration may be required).

Company news

First patient dosed in VBL Therapeutics’ phase 2 clinical trial of its anti-cancer gene therapy VB-111 in recurrent glioblastoma

VBL Therapeutics has announced that patient dosing has begun in a phase 2 clinical trial investigating VB-111 (ofranergene obadenovec) for the treatment of recurrent glioblastoma. The phase 2 study is enrolling patients with recurrent glioblastoma who are scheduled to undergo a second surgery. Granted fast track designation and orphan drug status by the FDA in 2013 for treating glioblastoma, VB-111 is an anti-cancer gene therapy designed to cut off the blood supply to tumours. Read more (company press release). Clinical trial information here (Clinicaltrials.gov).

Orbus Therapeutics announces a positive outcome for interim ‘futility analysis’ of phase 3 STELLAR study in anaplastic astrocytoma

Orbus Therapeutics has announced a positive outcome of the pre-planned interim analysis for futility in its phase 3 STELLAR clinical study of eflornithine in patients with recurrent anaplastic astrocytoma. In this trial, eflornithine with lomustine is being compared with lomustine alone. The pre-planned futility analysis was conducted by Orbus’ Independent Data Monitoring Committee (IDMC), an independent panel of experts that periodically monitors the safety and efficacy of the STELLAR study. Read more (company press release).

FDA fast track approval for Oblato’s OKN-007 for diffuse intrinsic pontine glioma

The US Food and Drug Administration (FDA) has granted fast-track status to OKN-007 for treating diffuse intrinsic pontine glioma (DIPG), Oblato has announced. The FDA Fast Track is designed to help speed development in the regulatory review of drugs to treat serious conditions and fill an unmet medical need. Read more (company press release).

First patient treated in phase 1 clinical trial of OS2966 in recurrent glioblastoma, OncoSynergy announces

OncoSynergy has announced that the first recurrent glioblastoma patient has been treated in its phase 1 clinical trial of its OS2966 immunotherapy (an anti-CD29 antibody). Taking place at Moffitt Cancer Center, Florida, USA, the trial (NCT04608812) will see the agent delivered directly into patients’ brain tumours via convection-enhanced delivery, whereby the drug passes through a thin catheter tube into the tumour site. Read more (company press release).

Nuvation Bio’s NUV-422 is awarded Orphan Drug Designation by US FDA for malignant gliomas

Nuvation Bio has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to NUV-422 for the treatment of patients with malignant gliomas. Orphan Drug Designation grants various development incentives, including tax credits for eligible clinical trials, waiver of application fees and market exclusivity for seven years upon FDA approval. NUV-422 inhibits three enzymes involved in cell growth and division – CDK 2, 4 and 6 – which can drive cancer cells to proliferate.  A phase 1/2 trial of NUV-422 in recurrent or refractory high-grade gliomas is currently underway. Read more (company press release). Clinical trial information here (Clinicaltrials.gov).

Bionaut Labs unveils its remote-controlled microscale robots for treating glioma

Bionaut Labs has revealed details of its new technology for treating brain tumours: remote-controlled microscale robots called Bionauts. Custom made for each purpose, these individual robots, which measure on the nanometre or millimetre scale, can be navigated through the spinal cord and brain using a compact magnetic controller and triggered to release a payload of a drug or other therapeutic agent at the target site. Read more (company press release).

International brain tumour community news

Brain and Spinal Tumors of Childhood second edition released

The second edition of Brain and Spinal Tumors of Childhood, edited by David A Walker, Giorgio Perilongo, Roger E Taylor and Ian F Pollack, has been published, coming at a time of paradigm shift in understanding the molecular pathology and neuroscience of brain and spinal tumours of childhood and their mechanisms of growth within the developing brain. The book reflects the growing concern to understand the impact of the tumour and its treatment upon the full functioning of a child’s developing brain. A chapter in the book also records the important work done by patient advocates around the world in supporting pediatric brain tumour patients and their families. The chapter has been co-authored by Bonita Suckling (South Africa), IBTA Chair Kathy Oliver, Mark Brougham and Sacha Langton-Gilks (United Kingdom), Gloria Garcia Castellvi (Spain), Anita Granero (Italy), Raees Tonse and Kathy Riley (United States), Rakesh Jalali (India), Susan Awrey (Canada) and Yuko Moue and Hisato Tagawa (Japan). Further information available here.

Event news

Due to the current COVID-19 pandemic, many in-person meetings and conferences around the world have been cancelled, postponed, or converted to virtual events. We are trying our best to keep up with this news but please make sure you check with conference organisers as to the status of their scheduled events.



Brain Tumour Foundation of Canada Webinar Series
Training the Next Generation of Neurosurgeon-Scientists: Fighting Brain Tumours in Two Worlds
20 April 2021

Webinar: Clinical Trials – Paving the Way Forward  (American Brain Tumor Association)
28 April 2021

US/Canada/Australia/New Zealand National Brain Tumour Awareness Month
See websites of US, Canadian, Australian and New Zealand brain tumour organisations for further details.

BT5K Your Way: a virtual 5K (American Brain Tumor Association) 
22 May 2021
Register your event online

Brain Tumour Foundation of Canada Webinar Series
Psychosocial Screening in Pediatric Brain Tumour Care
25 May 2021

Webinar: Neuropsychiatric Symptoms & How to Manage Them (American Brain Tumor Association)
26 May 2021

Brain Tumour Foundation of Canada Webinar Series
It’s All About Being Adaptive! Rehabilitation When You Have a Brain Tumour
22 June 2021

Brain Tumour Foundation of Canada Webinar Series
Navigating the Twists and Turns of Survivorship: School and Work Considerations for Youth and Young Adults
21 September 2021

Brain Tumour Foundation of Canada Webinar Series
Changing the Caregiver Experience: Ways to Take Charge and Support Yourself and Your Loved One Living with a Brain Tumour
26 October 2021

International Brain Tumour Awareness Week
30 October – 6 November 2021

Brain Tumour Foundation of Canada Webinar Series
Genomic and Molecular Markers in Glioma: Where Are We Now?
23 November 2021

SNO/NCI Joint Symposium: Targeting CNS Tumor Metabolism
6-7 April 2021
Maryland, USA

AACR Annual Meeting 2021 (Week 1)
10-15 April 2021

ISNOCON 2021 (Indian Society of Neuro-Oncology)
15-17 April 2021

AAN 2021 Virtual Annual Meeting
17-22 April 2021

6th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS) and 17th Meeting of the Asian Society for Neuro-Oncology (ASNO)
6-9 May 2021 Now postponed to 24-27 March 2022 (see below)
Seoul, South Korea

AACR Annual Meeting 2021 (Week 2)
17-21 May 2021

Cancer Research UK Cambridge Centre Neuro-oncology Conference 2021
18-19 May 2021

2021 ASCO Annual Meeting
4-8 June 2021

2021 SNO Pediatric Conference – 6th Biennial Pediatric Neuro-Oncology Basic and Translational Research Conference
10-12 June 2021
Washington, D.C., USA

Posterior Fossa Society – First Global Meeting
 Postponed to September 2022. Please check website for confirmation of new 2022 dates.
Liverpool, UK

Brain Tumor Epidemiology Consortium 22nd Annual Meeting (BTEC 2021)
“Brain Tumor Biomarkers: For Research, Clinics and Registries”
20-24 June 2021

Brain Tumors Meeting 2021
21-23 June 2021 Rescheduled to 22-24 June 2022
Warsaw, Poland

British Neuro-Oncology Society Annual Meeting (BNOS 2021)
8-9 July 2021

Basic and Translational Omics of Brain Tumors and Their Microenvieonment
15-16 July 2021

3rd Annual Conference on Brain Metastases
19-21 August 2021
Toronto, Canada

AANS 2021 Annual Scientific Meeting: “Neurosurgery United Stronger Together”
21-25 August 2021
Orlando, Florida, USA

2021 Congress of the European Association of Neuro-Oncology (EANO)
25-26 September 2021 [For the Educational Day see below in October]
Rotterdam, The Netherlands

Congress of Neurological Surgeons (CNS) 2021 Annual Meeting
16-20 October 2021
Austin, Texas, USA

2021 Congress of the European Association of Neuro-Oncology (EANO) Educational Day
23 October 2021

13th Annual Scientific Meeting of the Co-operative Trials Group for Neuro-Oncology (COGNO)
24–26 October 2021
Melbourne, Australia

Annual Scientific Meeting of the Society for Neuro-Oncology (SNO 2021)
18-21 November 2021
Boston, Massachusetts, USA


6th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS) and 17th Meeting of the Asian Society for Neuro-Oncology (ASNO)
24-27 March 2022
Seoul, South Korea

15th Congress of the International Stereotactic Radiosurgery Society (ISRS)
3-7 April 2022
Brisbane, Australia

11th Brain Tumor Meeting Berlin
19-20 May 2021
Berlin, Germany

Posterior Fossa Society – First Global Meeting
September 2022 – dates to be confirmed Please check website 2021 website for confirmation of new 2022 dates.
Liverpool, UK

16th Congress of the European Association of Neuro-Oncology (EANO)
15-18 September 2022  (further details available in due course)
Vienna, Austria

27th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO 2022)
16-20 November 2022
Tampa, Florida, USA

If you are organising or are aware of a forthcoming patient or brain tumour advocacy event or a scientific conference, whether it is virtual or in-person, taking place in 2021 or 2022 or are aware of any changes to the listings above, then please let us know by emailing kathy@theibta.org so that we can also include new events on our events page.

Keep up to date with future scientific conferences and events on the IBTA website conferences page here.



IBTA Website



Who we are

The International Brain Tumour Alliance was established in 2005. It is a network of support, advocacy and information groups representing brain tumour patients and carers in different countries and also includes researchers, scientists, clinicians and allied health professionals who work in the field of brain tumours.
For more information, please visit www.theibta.org.  


Tell us what you think!

We love to hear from you if you have any news that you would like to share with the IBTA community. Just send us an email: kathy@theibta.org.
We will do our best to relay as much information as possible to our subscribers via this monthly newsletter and our website. The selection of e-News entries is at the sole discretion of the editors.

Copyright © 2021 The International Brain Tumour Alliance, All rights reserved.
You are receiving this email because you are subscribed to IBTA e-News.

Our mailing address is:

The International Brain Tumour Alliance

PO Box 244


Surrey, KT20 5WQ

United Kingdom

Add us to your address book


The International Brain Tumour Alliance (IBTA) makes every effort to be accurate regarding the information contained in this e-News (or in any documents, reports, notes or other material produced for and on behalf of the IBTA to which we provide a link in this e-News).  However, the IBTA accepts no liability for any inaccuracies or omissions herein nor can it accept liability for any loss or damage resulting from any inaccuracy in this information or third party information such as information on websites to which we link. The information contained in this e-News is for educational purposes only and should in no way be taken as a substitute for medical care nor is the information on the IBTA website meant to constitute medical advice or professional services. For medical care and advice, please contact your doctor. Inclusion of clinical trial news does not imply the IBTA’s particular endorsement or not of any trial.

Other websites linked from the IBTA e-News are not under the control of the IBTA. Therefore we take no responsibility for their content. The IBTA has provided these links as a convenience to you and can in no way verify the information, quality, safety or suitability of linked websites.

Any company sponsorship of the IBTA’s projects does not imply the IBTA’s endorsement of any particular form or forms of therapy, treatment regimen or behaviour. (For further details of our sponsors, please see our Sponsorship Policy).

The views and opinions in the materials included in this e-News may not necessarily be those of the International Brain Tumour Alliance.